Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig Sells 3,392 Shares

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 3,392 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $22.86, for a total transaction of $77,541.12. Following the completion of the transaction, the chief executive officer now owns 1,222,005 shares of the company’s stock, valued at $27,935,034.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Chaim Indig also recently made the following trade(s):

• On Monday, April 8th, Chaim Indig sold 12,043 shares of Phreesia stock. The stock was sold at an average price of $22.62, for a total transaction of $272,412.66.

Phreesia Stock Performance

Shares of Phreesia stock traded up $0.16 during midday trading on Wednesday, hitting $23.16. The company had a trading volume of 383,738 shares, compared to its average volume of 522,719. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -9.13 and a beta of 0.92. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $24.56 and a 200 day simple moving average of $21.23. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $34.98.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. The business had revenue of $95.00 million for the quarter, compared to analysts’ expectations of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The business’s revenue was up 24.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.72) EPS. As a group, analysts predict that Phreesia, Inc. will post -1.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently made changes to their positions in PHR. Envestnet Asset Management Inc. boosted its stake in Phreesia by 11.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 9,692 shares of the company’s stock worth $255,000 after purchasing an additional 1,015 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Phreesia by 160.9% during the 1st quarter. JPMorgan Chase & Co. now owns 85,546 shares of the company’s stock valued at $2,254,000 after acquiring an additional 52,755 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Phreesia by 20.7% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 8,427 shares of the company’s stock valued at $222,000 after buying an additional 1,447 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Phreesia by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 219,598 shares of the company’s stock valued at $5,788,000 after buying an additional 2,047 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Phreesia by 27.6% in the first quarter. PNC Financial Services Group Inc. now owns 16,059 shares of the company’s stock valued at $424,000 after buying an additional 3,473 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. JMP Securities boosted their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock a “market outperform” rating in a report on Thursday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Friday, March 15th. Royal Bank of Canada reissued a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a research note on Thursday, March 21st. Canaccord Genuity Group increased their target price on shares of Phreesia from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, Barclays assumed coverage on shares of Phreesia in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $29.00 target price on the stock. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.62.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.